Abstract
Purpose
Materials and Methods
Results
Figures and Tables
Fig. 1
Plot showing a trend for the total infants below 12 months of age who visited our hospital (black line), and total diagnosed and treated intussusception infants below 12 months of age in our hospital (gray line) between 2005 and 2013. The tendency of intussusception decreased across most of the years studied. The reason for the increased number of intussusceptions in 2012 remains unclear.
![ymj-58-631-g001](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-g001.jpg)
Fig. 2
Number of incidents over the observation period divided into two-month intervals. A periodic increase in incidents is seen; however, the overall pattern is a decline in incidence. The incidence rate was calculated using standard poisson-based methods, and a decrease in the risk ratio by 0.51 was observed.
![ymj-58-631-g002](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-g002.jpg)
Table 1
Total RotaTeq® Doses Administered and Total Infants Vaccinated during the Study Period
![ymj-58-631-i001](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i001.jpg)
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | Total | |
---|---|---|---|---|---|---|---|---|
Total doses | 52 | 983 | 1650 | 1718 | 1974 | 2045 | 2108 | 10530 |
Total infants | 47 | 466 | 644 | 724 | 731 | 781 | 813 | 4206 |
Table 2
Total RotaTeq® Vaccinations Administered and the Number of Vaccinations Given One, Two, or Three Doses
![ymj-58-631-i002](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i002.jpg)
Total | 10530 |
Dose 1 | 4206 |
Dose 2 | 3446 |
Dose 3 | 2878 |
Table 3
Number of Total Visited Infants, IS Diagnosed Infants, and IS Diagnosed Infants during Risk Window Period
![ymj-58-631-i003](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i003.jpg)
Table 4
Number of Infants Diagnosed with IS at our Facility and the Number of Infants Younger Than 12 Months Who Have Visited Our Facility
![ymj-58-631-i004](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i004.jpg)
2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | Total | |
---|---|---|---|---|---|---|---|---|---|---|
IS | 34 | 38 | 60 | 45 | 31 | 37 | 44 | 25 | 20 | 334 |
Infants visiting | 3798 | 9939 | 5902 | 6816 | 6669 | 7326 | 7519 | 7894 | 8052 | 63915 |
Table 5
Results from Our Facility Compared to Those from the VSD Project Conducted in the United States, Which Investigated Pentavalent Vaccine-Associated IS
![ymj-58-631-i005](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i005.jpg)
VSD, Vaccine Safety Datalink; IS, intussusception; CIF, comparative incidence figure; CI, confidence interval.
When we used CIFs, the rotavirus vaccine-associated IS rate at our facility was 31.63 times higher than that of the United States report. However, after taking into consideration the difference in the background incidence rate of IS between the two countries, the incidence rate was seven times higher in our hospital. However, one thing that needs to be considered here is that our data, which are from a single center study, are smaller compared to the United States data. Also, given that our facility is a tertiary medical center, the number of patients diagnosed and treated for IS may be much higher than the number of patients who visit for the sole purpose of receiving vaccinations. These factors could have contributed to such discrepancy.
Table 6
Expected Rate per Vaccination Calculated Using the Background Rate
![ymj-58-631-i006](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i006.jpg)
Doses | No. of doses | No. of cases of IS | Relative risk | 95% CI | |
---|---|---|---|---|---|
Observed | Expected | ||||
All doses | 10530 | 2 | 1.91 | 1.05 | 0.12–5.12 |
Dose 1 | 4206 | 0 | 0.63 | - | |
Dose 2 | 3446 | 2 | 0.62 | 3.21 | 0.36–15.65 |
Dose 3 | 2878 | 0 | 0.52 | - |
IS, intussusception; CI, confidence interval.
Based on the assumption that IS is not associated with rotavirus vaccination, we calculated the relative risk and 95% CI for the total doses and for those who received the second dose. The results indicate that there is no association between the rotavirus vaccination and IS.
Table 7
Examination of the Rotavirus Antigen Test Results from 2005 to 2014 at Our Facility
![ymj-58-631-i007](/upload/SynapseData/ArticleImage/0069ymj/ymj-58-631-i007.jpg)
ACKNOWLEDGEMENTS
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)